Corvus Pharmaceuticals

OverviewSuggest Edit

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. The Company is developing new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.

TypePublic
Founded2014
HQBurlingame, US
Websitecorvuspharma.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)49(-10%)
Job Openings1
Share Price (Feb 2020)$3.7 (-1%)

Key People/Management at Corvus Pharmaceuticals

Board of Directors

Board of Directors

Ian T. Clark

Corvus Pharmaceuticals Office Locations

Corvus Pharmaceuticals has an office in Burlingame
Burlingame, US (HQ)
863 Mitten Rd #102
Show all (1)

Corvus Pharmaceuticals Financials and Metrics

Corvus Pharmaceuticals Revenue

USD

Net income (Q3, 2019)

(11.0m)

EBIT (Q3, 2019)

(11.5m)

Market capitalization (26-Feb-2020)

109.1m

Closing stock price (26-Feb-2020)

3.7

Cash (30-Sept-2019)

9.1m

EV

102.6m
Corvus Pharmaceuticals's current market capitalization is $109.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

7.6m10.2m10.6m

R&D expense

29.4m46.3m38.6m

Operating expense total

37.0m56.5m49.2m

EBIT

(37.0m)(56.5m)(49.2m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

General and administrative expense

1.0m1.7m2.8m2.7m2.8m2.2m2.5m2.5m2.8m2.9m3.0m2.5m

R&D expense

5.4m7.1m7.7m13.5m12.4m10.7m12.1m9.7m8.4m9.4m10.6m9.0m

Operating expense total

6.4m8.8m10.5m16.2m15.2m12.9m14.6m12.3m11.1m12.3m13.6m11.5m

EBIT

(6.4m)(8.8m)(10.5m)(16.2m)(15.2m)(12.9m)(14.6m)(12.3m)(11.1m)(12.3m)(13.6m)(11.5m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

5.1m45.1m39.2m

Prepaid Expenses

1.1m1.2m992.0k

Current Assets

136.0m91.2m115.6m

PP&E

3.2m2.7m2.2m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(161.0k)(55.7m)(46.9m)

Depreciation and Amortization

842.0k847.0k

Accounts Payable

1.9m1.6m(1.5m)

Cash From Operating Activities

(46.2m)(41.0m)
USDY, 2019

EV/EBIT

-8.9 x

EV/CFO

-3.6 x

Financial Leverage

1.1 x
Show all financial metrics

Corvus Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

11

Patents Licensed

18
Show all operating metrics

Corvus Pharmaceuticals Online and Social Media Presence

Embed Graph

Corvus Pharmaceuticals News and Updates

Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy

Thinking about buying stock in Corvus Pharmaceuticals, Fitbit, Intel, Sprint, or Slack Technologies?

NEW YORK, Dec. 6, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, FIT, INTC, S, and WORK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting

 Clinical and laboratory results support a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production

Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

BURLINGAME, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present at the Jefferies 2019 Global …

Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT
Show more

Corvus Pharmaceuticals Blogs

Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium

BURLINGAME, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller , M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted

Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium

BURLINGAME, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated

Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to

Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting

BURLINGAME, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that

Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

BURLINGAME, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that

Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019

Event will provide a review of updated CPI-006 data from Phase 1/1b study and data on adenosine gene signature in renal cell cancer with ciforadenant presented at SITC 2019 BURLINGAME, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
Show more

Corvus Pharmaceuticals Frequently Asked Questions

  • When was Corvus Pharmaceuticals founded?

    Corvus Pharmaceuticals was founded in 2014.

  • Who are Corvus Pharmaceuticals key executives?

    Corvus Pharmaceuticals's key executives are Board of Directors.

  • How many employees does Corvus Pharmaceuticals have?

    Corvus Pharmaceuticals has 49 employees.

  • Who are Corvus Pharmaceuticals competitors?

    Competitors of Corvus Pharmaceuticals include Northwest Biotherapeutics, CytomX Therapeutics and TESARO.

  • Where is Corvus Pharmaceuticals headquarters?

    Corvus Pharmaceuticals headquarters is located at 863 Mitten Rd #102, Burlingame.

  • Where are Corvus Pharmaceuticals offices?

    Corvus Pharmaceuticals has an office in Burlingame.

  • How many offices does Corvus Pharmaceuticals have?

    Corvus Pharmaceuticals has 1 office.